Comparative population pharmacokinetics of lorazepam and midazolam during long‐term continuous infusion in critically ill patients

Abstract

AimsIt is well established that there is a wide intra-and interindividual variability in dose requirements for lorazepam and midazolam in intensive care patients. The objective of this study was to compare the population pharmacokinetics of lorazepam and midazolam after long-term continuous infusion in mechanically ventilated critically ill patients. MethodsForty-nine critically ill patients randomly received either lorazepam (n = 28) or midazolam (n = 21) by continuous infusion for at least 24 h. Multiple blood samples were obtained for determination of the drug and metabolite concentrations by H PLC. Population pharmacokinetic models were developed using the Non-Linear Mixed Effect Modelling (NONMEM) program. The influence of selected covariates was investigated. The prospective performance of the models was evaluated on the basis of results in separate groups of patients for lorazepam (n = 31) and midazolam (n = 33).

Population Pharmacokinetics of Ceftazidime in Intensive Care Unit Patients: Influence of Glomerular Filtration Rate, Mechanical Ventilation, and Reason for Admission

“…This heterogeneity is well known to produce high variability in pharmacokinetic parameters, as was previously demonstrated for the clearance and the total volume of distribution (15,26,36). Ceftazidime pharmacokinetics in critically ill patients is altered by an increased volume of drug distribution and a longer elimination half-life (16).…”

Maintaining comfort, cognitive function, and mobility in surgical intensive care unit patients

“…Benzodiazepines are metabolized by the liver through cytochrome p450 system and glucuronide conjugation and, as such, may interfere with other cytochrome p450Ymediated medications. 88,89 In Long-term use may saturate peripheral tissues and lead to prolonged emergence from sedation…”

Champ 6 - pharmacologie des agents utilisés dans l’état de mal épileptique☆

“…Après administration de la solution injectable par voie rectale la biodisponibilité est de 50 à 80 % pour le diazépam et de 20 à 50 % pour le midazolam. L'absorption est très rapide avec un Tmax (temps correspondant à la concentration maximale observée [Cmax]) de 10, 20 à 60 et 15 à 20 minutes chez l'enfant, respectivement pour le diazé-pam, le clonazépam et le midazolam [4,[11][12][13][14][15][16][17][18][19][20]. La voie intramusculaire a été abandonnée car elle conduit à une absorption lente et erratique.…”